An observational study in Bronchiectasis, sponsored by National Taiwan University Hospital. Active, not recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by National Taiwan University Hospital · Observational
Bronchiectasis is a disease characteristic by bronchial dilatation. Bronchiectasis leads to further impairment of mucociliary clearance, causing a vicious cycle of further infection and progressive airway damage, resulting in poorer control of the primary disease. The clinical presentation is non-specific. The etiologies of bronchiectasis include post-infection, such as bacterial pneumonia, tuberculosis, or aspiration pneumonia, autoimmune disease, such as rheumatoid arthritis, or sjogren's syndrome, cystic fibrosis and immunoglobulin deficiency. The comorbidities of bronchiectasis include cardiovascular disease, cancer such as lung cancer, or esophageal cancer, gastro-oesophageal reflux disease and iron deficiency anemia. Treating these comorbidities will help for the prognosis of bronchiectasis. The treatment for bronchiectasis included airway clearance therapies, mucoactive medication, long term antibiotics and bronchodilator if indicated. Long term anti-inflammatory therapies are not suggested. Surgery is indicated if medical treatment failure and localized bronchiectasis or massive hemoptysis.
The different characteristics of bronchiectasis have been reported in different foreign studies. There were few studies in Taiwan. This is a prospective study to find the characteristics including comorbidities, severity, treatment in stable and exacerbation condition and pulmonary rehabilitation in Taiwan.
368 studies on the registry are indexed under Bronchiectasis; 104 are open to participants now.
This study's planned enrollment of 200 is above the median of 160 across 132 observational studies indexed under Bronchiectasis.
Browse Bronchiectasis studies →National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
patients with BronchiEctaSis in Taiwan
Exclusion Criteria:
Number of participants with comorbidities
Comorbidities will be assessed at baseline and during research period using medical records and include cardiovascular disease, malignancy, autoimmune disease, and other chronic conditions.
Time frame: 30months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital